Jun 27, 2019
Global Hepatitis B Market Report 2019 - Key Marketed and Pipeline Drugs, Clinical Trials, Recent Events, Deals
Jun 19, 2019
High Point Clinical Trials Center Joins ProSciento's NASH PASS(TM) Initiative Focused on Accelerating NAFLD/NASH Clinical Trial Recruitment
Jun 18, 2019
DURECT Announces Completion of the 90 mg Severe Cohort and Dose Escalation Committee Approval to Commence 150 mg Dosing in Patients with Severe Alcoholic Hepatitis (AH) in its Ongoing DUR-928 Phase 2a AH Trial
Jun 17, 2019
Zydus Announces Completion of Enrolment in EVIDENCES IV Phase 2 Clinical Trial of Saroglitazar Magnesium in NASH
Jun 12, 2019
Cirius Therapeutics Expands Scientific Advisory Board
Jun 11, 2019
NASH kNOWledge Joins Global International Nonalcoholic Steatohepatitis (NASH) DAY to Raise Disease Awareness
Jun 09, 2019
VeroScience Presents New Pipeline Data for Metabolic Disease Therapies at 2019 American Diabetes Association Meeting
Jun 05, 2019
Interim Data on Cirius Therapeutics' MSDC-0602K to be Presented at the American Diabetes Association Scientific Sessions
Jun 03, 2019
Cirius Therapeutics Adds to Leadership Team
May 30, 2019
Scientists Bioengineer Human Liver Disease in the Lab to Find New Treatments
May 22, 2019
Scientists Identify New Therapeutic Target for Fatty Liver Disease
May 21, 2019
NetNoggin® announces the release of NetNog: #genesis® NASH (including NAFL)
May 07, 2019
DURECT Corporation Announces First Quarter 2019 Financial Results and Update of Programs
May 03, 2019
DURECT Corporation to Present Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial and Report First Quarter 2019 Financial Results
May 01, 2019
Akero Therapeutics Appoints Life Sciences Investment Banking Veteran Bill White as Chief Financial Officer and Head of Corporate Development
Apr 30, 2019
Taiwan National Health Insurance Administration of the Ministry of Health and Welfare Approves Vemlidy(R) (tenofovir alafenamide) for Reimbursement
Apr 30, 2019
Galmed Pharmaceuticals to Report First Quarter 2019 Financial Results and Provide Business Update on Tuesday, May 7
Apr 24, 2019
The Rising Crisis: How America´s Lifestyle Pushes it to the Verge of a Liver Disease Epidemic
Apr 23, 2019
HEC TaiGen Initiates Phase III Trial of Combination of Furaprevir and Yimitasvir for the Treatment of Chronic Hepatitis C Patients in China
Apr 18, 2019
Bioclinica Launches NAFLD/NASH Clinical Trials Practice